The company's approach centers on targeted therapies and immuno-oncology, including next-generation PD-1/PD-L1 modulation and RAS-targeted therapies. The company highlights a combination therapy strategy and describes an ultimate goal of transforming deadly cancer into a chronic and eventually curable disease.
Cyborg Score Rationale
Adlai Nortye is in the clinical stage, with multiple candidates in various phases of development but no product revenue reported. The Phase III lead candidate shows progress, but commercialization risk remains significant. The company has a diversified pipeline addressing multiple cancer types.
Top Insights
Multi-indication pipeline spanning PI3K, PD-L1, EP4 antagonist, and RAS-targeted therapies with Phase I, Ib, and III stage candidates
Lead program AN2025 (buparlisib) addresses immunotherapy-resistant HNSCC, a significant unmet need with accelerated approval potential
Global Phase III trial with 483 patients across 18 jurisdictions demonstrates scale and global regulatory ambitions
Strategic partnerships including in-licensing from Novartis and private placement with Nippon Kayaku indicate pharma validation
Named Competitors
PI3K inhibitors — Competing PI3K pathway modulators in oncology
PD-L1 inhibitors — Established checkpoint inhibitor players
RAS-targeted agents — RAS pathway therapeutics for solid tumors
Recent Developments
(September 2023) IPO completion on NASDAQ at revised terms following initial postponement
(2023-2024) Phase III BURAN trial ongoing for lead candidate AN2025 in HNSCC
(January 2026) Stock trading at $6.53 with ~$128M market capitalization
Open the full interactive Adlai Nortye Ltd. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.